Zevra Therapeutics, Inc. (ZVRA)

8.33 -0.06 (-0.72%) USD  |  NASDAQ  |  Dec 12, 16:00
8.25 -0.08 (-0.96%) After-Hours: 20:00
More

Zevra Therapeutics Research and Development Expense (Quarterly): 3.432M for Sept. 30, 2025

Research and Development Expense (Quarterly) Chart

View Research and Development Expense (Quarterly) for ZVRA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
Nektar Therapeutics 27.25M
XOMA Royalty Corp. 0.069M
Akebia Therapeutics, Inc. 14.63M
NovaBay Pharmaceuticals, Inc. --
Palatin Technologies, Inc. 2.526M